A Non-Randomized, Open-Label, Three-Part, Drug-Drug Interaction Study to Evaluate the Effects of EDP-938 on the Pharmacokinetics of Tacrolimus, Dabigatran, Rosuvastatin and Midazolam in Healthy Subjects
Latest Information Update: 21 Sep 2022
At a glance
- Drugs Zelicapavir (Primary) ; Dabigatran etexilate; Midazolam; Rosuvastatin; Tacrolimus
- Indications Respiratory syncytial virus infections
- Focus Pharmacokinetics
- Sponsors Enanta Pharmaceuticals
- 12 Oct 2021 Status changed from recruiting to completed.
- 10 Mar 2021 Number of arms changed from 3 to 4. Drug Midazolam and experimental arm: EDP-938 and midazolam interaction (Part 4) added to study protocol. Planned number of patients increased.
- 10 Mar 2021 Planned number of patients changed from 72 to 96.